• Decrease font size
  • Default font size
  • Increase font size
License Agreement for World Wide Exploitation of Technology PDF Print E-mail
Tuesday, 19 December 2006 12:54
Prosonix Limited (Oxford, UK) announce the signing of a far reaching License Agreement for the commercial application of Prosonix’s proprietary C3 sonocrystallization technology at Alcoa’s alumina refineries worldwide.
Translate from en to arTranslate from en to zh-CNTranslate from en to zh-TWTranslate from en to nlTranslate from en to frTranslate from en to deTranslate from en to elTranslate from en to itTranslate from en to jaTranslate from en to koTranslate from en to pt-PTTranslate from en to ruTranslate from en to es
 

Navigation

Home
Product Pipeline
PSX1001
PSX1002
PSX2000 Series
Partners
Pharmaceuticals
Inhalation
Combination Therapy
Market Opportunity
Technology
UMAX
SAX™
Sonocrystallization
DISCUS™
Ultrasonic Particle Rounding
CrystalGEM™
Intellectual Property
FDA Quality by Design
About Us
Board of Directors
Management Team
Collaborations
Investors
News
Events
Contact
How to find us
 
 

Latest News

03 Feb 2012 - Geoff Down appointed as Chief Medical Officer
Prosonix Appoints Respiratory Drug Development Expert Dr Geoff Down as Chief Medical Officer Prosonix (Oxford, UK), an emerging pharmaceutical company developing a portfolio of enhanced respiratory...
More in: Latest

Events

Respiratory Drug Delivery 2012
10 October 2011 08:57
article thumbnai